Paradigm Biopharmacueticals has executed an exclusive license agreement with the Icahn School of Medicine at Mount Sinai for the treatment of a rare inherited disease which cases include debilitating joint pain and dysfunction, as reported by SmallCaps writer, George Tchetvertakov. Australian-based Publicly traded Paradigm Biopharmaceuticals (ASX:PAR) continues to expand the range of applications for its proprietary Pentosan Polysulfate Sodium (iPPS) drug by executing an agreement with Mount Sinai. The writer reports that iPPS is making good progress in clinical trials in Australia. Paradigm and Mount Sinai announced an exclusive “in-license agreement” where Mount Sinai will use the intellectual property in the treatment of mucopolysaccharidoses (MPS), a group of inherited lysosomal storage disorders.
According to recent research, MPS affects approximately 3.5 in 100,000 live births and presents in three different ways including 1) Dysmorphic syndrome 2) in learning disabilities and behavioral health issues and dementia and 3) severe bone dysplasia, colloquially known as “dwarfism.”